SALES: (973) 586-4421
MARKETING: (973) 586-4421

United States
Canada
Mexico
China
Middle East

Home
Patient LoginGain Access
Pharmacy LoginMust Register
Contact UsRequest Information
RegistrationBecome a Patient
Company DirectoryDoctors and Staff
Who We AreMore About Us
Press and MediaIn The Press
What We CreatedOur Product List
Investor RelationsContact For More Info
About UsEmphyCorp
Alain MartinEmphyCorp CEO
Robert MillarEmphyCorp President & Director
Stanley E. KatzMedical Professor
Ronald J. Amen, Ph.DGlobal Regulatory Director & Director of EmphyCorp
Robert M. Irbe, Ph.DMedical Professor
R. Dale WingetGeneral Counsel
Dr. William MartinSecretary and Treasurer
Roger S. Thrall, Ph. DMedical Professor
Our ProductsHealth Products
Non-Steroidal COPD SprayPatented Rx Technology
N115 Non-Steroidal COPD/Pulmonary Fibrosis Nasal SprayPatented Rx Technology
COPD Spray70% Lower Steroids (Patented Rx Technology)
Alzheimer's Nasal SprayPatented Rx Technology
Smoking Cessation Oral SprayPatented Rx Technology
Drug Free Cancer Pre-TreatmentPatented Rx Technology
ConditionsWhat We Can Treat
COPDChronic Pulmonary Disease
AsthmaEmphyClear Treatments
EmphysemaHelpfull Treatments
SarcoidosisWhat Is It?
Cystic FibrosisHelpful Recommendations
Chronic BronchitisKnown Treatments
Interstitial Lung DiseaseHow To Treat It
Viral infectionWhich Product To Use
Bacterial InfectionWhat Product To Use
PULMONARY FIBROSISTREATMENT (NEW)
FDA SubmissionsFind Out More
N115 FDA SubmissionsProprietary Ingredient
Nitric OxideRegulating Intake Levels
Sodium PyruvateUsage with Nitric Oxide
Our Medical StudiesEmphyCorp Medical Journal
Our BlogMedical Blog
Web LinksOur Supporters
Medical NewsWeekly News
Featured ArticlesNews Alerts
Patient TestimonialsFrom Our Patients
Doctor TestimonialsWhat Our Clinics Say
Pharmacy TestimonialsWhat Our Pharmacies Say

Thursday, 06 August 2020

HomePatient Testimonials

Patient Testimonials

“Coming Soon"

“Coming Soon"

"Coming Soon"

Find a Retailer

Find a Local Retailer Nearest You for Your EmphyCorp Product Line

Find a Retailer

Respiratory

Asthma
Bronchitis
Emphysema
Cystic Fibrosis

Video Archive

How It Works
Patent Formula
Using The Medication
History of EmphyCorp

In The Media

Press Releases
New Products
Video Archive
Get In Touch

Our Products

Please see "Our Products" Tab on the Home Page

Patient Inquiries

Contact EmphyCorp
Frequent Questions
Privacy Policies
Patient Disclaimer

United States
Canada
Mexico
China
Middle East

The FDA has determined that N115 has sufficient safety toxicology and clinical data to proceed with the multi-dose, extended use, clinical trials. Phase III/Phase IV studies will focus on Pulmonary Fibrosis, Unmet Needs, and COPD patients. On the basis of existing clinical data, EmphyCorp is confident that its Investigative New Drug, N115, can and will be used for maintenance or continuous treatment of patients over extended periods of time. The Company believes that N115 will set the standard in the pharmaceutical industry for the treatment of major pulmonary diseases.

EmphyCorp and EmphyCorp.com does not encourage the use of any illegal substances. Always consult your local physician before taking any medication. Medications described on our website are for informational purposes ONLY and must be prescribed by your primary physician and scheduled for pickup at your local pharmacy. We are not a pharmacy and do not sell any prescription medications through this website.

EmphyCorp Inc - Copyright © 2013 | Terms and Conditons | Investor Relations | Become a Retailer | Informed Consent